Michaela Fleming

The findings of the retrospective cohort study were presented in a poster at IDWeek 2019.

The findings of the study were presented in an oral abstract presentation at the Annual Conference on Retroviruses and Opportunistic Infections (CROI 2019) in Seattle, Washington.

A New Drug Application (NDA) and a supplemental NDA (sNDA) were accepted for the Priority Review for products being developed by Merck.

A new study examining HIV in people who inject drugs found interventions increased use of antiretroviral medication.

Officials with the FDA have approved Grifols’ new formulation of immune globulin (GamaSTAN) for hepatitis A virus and measles post-exposure prophylaxis.

The new formulation is the only immune globulin available in the United States that is approved for post-exposure protection against hepatitis A and measles.

A new study suggests that pre-exposure prophylaxis (PrEP) could also serve as a gateway to primary care services.

The FDA has approved, under Priority Review, GlaxoSmithKline (GSK)’s tafenoquine (Krintafel), which is the first single-dose medicine for the prevention of Plasmodium vivax (P vivax) malaria relapse in patients over the age of 16 years who are receiving antimalarial therapy.

Approval for tafenoquine was granted based on the efficacy and safety data gleaned from a comprehensive global clinical development program for P vivax prevention of relapse,

Although resistance can be attributed to many different causes, inappropriate prescribing is arguably one of the main contributors.

The phase 3 randomized, double-blind study evaluated a single dose of baloxavir marboxil compared with placebo and oseltamivir in individuals aged 12 and older.

An experimental HIV-1 vaccine regimen was well-tolerated and produced immune responses against HIV in humans and rhesus monkeys.

This medication represents a new treatment for patients with cUTI, including pyelonephritis, due to certain Enterobacteriaceae.

Officials with the FDA have approved plazomicin (Zemdri, Achaogen) for the treatment of adults with complicated urinary tract infections (cUTIs), caused by certain Enterobacteriaceae, in patients with limited or no alternative treatment.